Literature DB >> 31740206

Hype or hope: Vagus nerve stimulation against acute myocardial ischemia-reperfusion injury.

Mingxian Chen1, Xuping Li1, Hui Yang1, Jianjun Tang1, Shenghua Zhou2.   

Abstract

Acute myocardial infarction (MI) is a major cause of death worldwide. Although timely and successful reperfusion could reduce myocardial ischemia injury, limit infarct size, and improve ventricular dysfunction and reduce acute mortality, restoring blood flow might also lead to unwanted myocardial ischemic-reperfusion (I/R) injury. Pre-clinical studies have demonstrated that multiple approaches are capable of attenuating the myocardial I/R injury. However, there is still no effective therapy for preventing myocardial I/R injury for the clinical setting. It is known that myocardial I/R injury could induce cardiac autonomic imbalance with over-activated sympathetic tone and reduced vagal activity, in turn, contributing to pathogenesis of myocardial I/R injury. Cumulative evidence shows that the enhancement of vagal activity, so called vagus nerve stimulation (VNS), is able to reduce injury and promote recovery of injured myocardium. Therefore, VNS might be a potentially novel strategy choice for preventing/attenuating myocardial I/R injury. In this review, we describe the protective role of VNS in myocardial I/R injury and related potential mechanisms. Then, we discuss the challenge and the opportunity of VNS in the treatment of acute myocardial I/R injury.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Acute myocardial ischemic reperfusion injury; Apoptosis; Inflammation; Oxidative stress; Vagus nerve stimulation

Mesh:

Year:  2019        PMID: 31740206     DOI: 10.1016/j.tcm.2019.10.011

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  8 in total

Review 1.  The autonomic nervous system in septic shock and its role as a future therapeutic target: a narrative review.

Authors:  Marta Carrara; Manuela Ferrario; Bernardo Bollen Pinto; Antoine Herpain
Journal:  Ann Intensive Care       Date:  2021-05-17       Impact factor: 6.925

2.  Non-invasive Autonomic Neuromodulation Is Opening New Landscapes for Cardiovascular Diseases.

Authors:  Mingxian Chen; Songyun Wang; Xuping Li; Lilei Yu; Hui Yang; Qiming Liu; Jianjun Tang; Shenghua Zhou
Journal:  Front Physiol       Date:  2020-12-15       Impact factor: 4.566

3.  MicroRNA-489 Promotes the Apoptosis of Cardiac Muscle Cells in Myocardial Ischemia-Reperfusion Based on Smart Healthcare.

Authors:  Wenhua Li; Yixin Zhang; Jian Wang; Qiang Li; Di Zhao; Bozan Tang; Shiwei Wang; Haifeng Shao
Journal:  J Healthc Eng       Date:  2022-01-07       Impact factor: 2.682

4.  Bilateral Superior Cervical Sympathectomy Activates Signal Transducer and Activator of Transcription 3 Signal to Alleviate Myocardial Ischemia-Reperfusion Injury.

Authors:  Lixia Li; Jiahong Gao; Lin Gao; Le Li; Hongfei Zhang; Wei Zhao; Shiyuan Xu
Journal:  Front Cardiovasc Med       Date:  2022-04-01

Review 5.  Preclinical multi-target strategies for myocardial ischemia-reperfusion injury.

Authors:  Yuqing Li; Yi Gao; Guangping Li
Journal:  Front Cardiovasc Med       Date:  2022-08-22

Review 6.  Opportunities and challenges of pain-related myocardial ischemia-reperfusion injury.

Authors:  Wenhua Jiang; Yue Yin; Xiaoming Gu; Zihui Zhang; Heng Ma
Journal:  Front Physiol       Date:  2022-09-02       Impact factor: 4.755

7.  The Effect of miR-505-5p on Inhibition of Serum Uromodulin Ameliorates Myocardial Inflammation and Apoptosis Induced by Ischemia-Reperfusion.

Authors:  Dongsheng He; Jun Hu; Yuhai Lu; Weikun Jia; Minxue Wei; Xiaofei Zeng; Hong Wang
Journal:  Oxid Med Cell Longev       Date:  2022-10-03       Impact factor: 7.310

8.  A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.

Authors:  Michael J Fossler; Virginia Schmith; Stephen A Greene; Lauren Lohmer; Michael S Kramer; Kelly Arscott; Ian E James; Mark A Demitrack
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.